Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.

Zhang F, Parayath NN, Ene CI, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT. · 2019

Read Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. by Zhang F, Parayath NN, Ene CI, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6722139.txt.

Introduction

Zhang and co-authors built a nanoparticle that reprograms tumor macrophages. Macrophages inside tumors usually take a form that shields the cancer and calms immunity. Flipping them to an attacking form could help, but broad attempts inflame the whole body. The team aimed mRNA carriers at these cells alone.

The particles deliver mRNA coding for a transcription factor and its activating kinase. In mouse models of ovarian cancer, melanoma, and brain tumors, infusions flipped the macrophages. The reprogrammed cells sparked anti-tumor immunity and shrank tumors. Repeated doses proved safe in the tests. The approach could one day treat suppressive tumors without disturbing the wider immune system.

Catalog record

CREATORZhang F, Parayath NN, Ene CI, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6722139

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers By F. Zhang, N. N. Parayath, C. I. Ene, S. B. Stephan, A. L. Koehne, M. E. Coon, E. C. Holland, M. T. Stephan Published in: Nature Communications DOI: 10.1038/s41467-019-11911-5 ABSTRACT Tumor-associated macrophages (TAMs) usually express an M2 phenotype, which enables them to perform immunosuppressive and tumor-promoting functions. Reprogramming these TAMs toward an M1 phenotype could thwart their pro-cancer activities and unleash anti-tumor immunity, but efforts to accomplish this are nonspecific and elicit systemic inflammation. Here we describe a targeted nanocarrier that can deliver in vitro-transcribed mRNA encoding M1-polarizing transcription factors to reprogram TAMs without causing systemic toxicity. We demonstrate in models of ovarian cancer, melanoma, and glioblastoma that infusions of nanoparticles formulated with mRNAs encoding interferon regulatory factor 5 in combination with its activating kinase IKKβ reverse the immunosuppressive, tumor-supporting state of TAMs and reprogram them to a phenotype that induces anti-tumor immunity and promotes tumor regression. We further establish that these nanoreagents are safe for repeated dosing. Implemented in the clinic, this immunotherapy could enable physicians to obviate suppressive tumors while avoiding systemic treatments that disrupt immune homeostasis. INTRODUCTION Tumor-associated macrophages (TAMs) are one of the most abundant non-neoplastic cell types found in discrete cancer locales1. Just like in healthy tissues, where macrophages have a remarkable ability for responding to environmental cues, TAMs are educated by the tumor microenvironment they experience. This produces multiple phenotypes that have a broad range of functions. TAM phenotypes can be described along a linear scale, where M1 and M2 phenotypes represent the two extremes (comparable to the TH1–TH2 classification)2,3. M1 macrophages are recognized as classically activated macrophages that can phagocytose pathogens. More importantly, these cells have anti-tumoral properties4,5. Unfortunately, other macrophages are polarized into the M2 phenotype. These decrease inflammation, encourage tissue repair, and provide pro-tumoral effects6. In established progressive tumors in humans, TAMs usually express an M2-like phenotype, and thus promote tumor progression, metastasis, and resistance to chemotherapy7–9. It is therefore of key interest in cancer research to create strategies that can reprogram TAMs from a pro-tumoral (M2-like) to an anti-tumor (M1-like) phenotype and thereby induce immune effects that can bring about tumor regression. However, as yet there are no methods that can enable physicians to rationally and selectively reprogram TAMs for therapeutic purposes10. For example, interleukin-12 (IL-12), IFN-γ, Toll-like receptor (TLR-) agonists, and CD40 agonists have all been reported to induce repolarization of TAMs11–13. However, these immunomodulatory agents can activate a broad range of cell types, which means they are associated with dose-limiting adverse effects and systemic toxicities14–16. Likewise, several small molecule drugs have been developed that focus on blocking the localization of TAM-precursor cells to tumors by targeting pathways involved in cell recruitment or expansion (e.g., inhibitors of CSF-1/CSF-1R17,18 or CCL219). Unfortunately, these approaches do not specifically promote macrophage anti-tumor activities and require repeated systemic exposure to large doses of the drugs. Furthermore, clinical trials of these pharmaceuticals produced low responses unless they were combined with cyto-reductive therapies or checkpoint blockade inhibitors19,20. Another factor that complicates the clinical use of CSF-1R inhibitors is the systemic depletion of normal monocytic cells, which causes high toxicity if patients are treated for prolonged periods21. Taking advantage of the very efficient phagocytic uptake of particles by macrophages, conventional nanocarriers such as liposomes have been formulated with bisphosphonates or other anti-proliferative agents (e.g., liposomal-clodronate)22 as a means to systemically deplete these cells, which are replaced via natural regeneration mechanisms. Also, oncolytic viruses have been used to deliver siRNA to silence immune-evasion pathways within tumors and indirectly promote phagocytosis of TAMs23. However, neither of these approaches reprograms existing macrophages with tumor-fighting capabilities. Macrophage mannose receptor 1 (MRC1), also known as CD206, is a type I transmembrane protein that belongs to the C-type lectin family. This receptor is expressed by macrophages and dendritic cells24. M2-like TAMs are derived from circulating monocytes that already express CD206, which is further upregulated upon extravasation of the cells at the tumor site and by exposure to factors in the perivascular tumor microenvironment25. Because CD206 shows high expression levels in TAMs, strategies that optimize the uptake of therapeutics via these receptors have the potential to be extremely powerful. Furthermore, this directed uptake is likely to require smaller treatment doses, thereby reducing the toxicity of the delivered substances. Huhn et al., for instance, functionalized polymer nanogels as potential drug nanocarriers with a Nanobody specific for CD20626, and similar concepts have been described by other groups to preferentially target TAMs while minimizing uptake by normal macrophages27,28. In vitro-transcribed (IVT) mRNA has recently come into focus as a potential new drug class for delivering genetic information directly into existing cells29. These synthetic medicines can be engineered to induce the transient expression of selected proteins because they structurally resemble natural mRNA. They are easily developed, inexpensive to produce, and efficiently scalable for manufacturing purposes30. Advances in addressing the inherent challenges of this drug class, particularly related to controlling translational efficacy and immunogenicity of the IVT mRNA, have provided the basis for a broad range of potential applications31–33. In fact, clinical development of mRNA-based therapeutics has led to the formation of several university spin-off companies (for example, Argos Therapeutics, BioNTech, CureVac, eTheRNA, Ethris, Factor Bioscience, Moderna, and Onkaido), which are supported by considerable venture capital inflows to develop mRNA-based cancer immunotherapies and infectious disease vaccines34. Here, we explore the use of IVT mRNA formulated into an injectable therapeutic that can genetically re-program TAMs into antitumor macrophages without disrupting immune homeostasis or causing systemic toxicity (Fig. 1). We find that we can condense and protect IVT mRNA, and target the genes it carries to M2-like macrophages by formulating the message into biodegradable polymeric nanoparticles (NPs)35. To provide the targets with genes encoding master regulators of macrophage polarization, we first establish that co-expression of Interferon Regulatory Factor 5 (IRF5)36 and IKKβ (a kinase that phosphorylates and activates IRF537) imprints TAMs with a potent pro-inflammatory and cytotoxic M1 phenotype. Using in vivo test systems that faithfully model advanced-stage ovarian cancer, metastatic melanoma, and glioblastoma, we establish that serial administration of IRF5/IKKβ-encoding NPs (via an intraperitoneal route for ovarian cancer, and injected intravenously to treat melanoma lung metastases or glioblastoma) substantially reduce tumor progression and, in some animals, even clear the disease. Phenotypic, functional, and gene expression studies reveal a dramatically reduced density of M2-like macrophages in tumor lesions of IRF5/IKKβ NP-treated mice compared to controls, along with increased numbers of inflammatory myeloid cells with distinct M1-type transcriptional profiles. Based on these data, our next step is to translate this technology into a clinical trial as an approach to treat ovarian cancer patients who were not responsive to other therapies. Although we will test IRF5/IKKβ NPs as a monotherapy first, our platform could ultimately reveal its full potential when used in synergy with existing immunotherapies, (e.g., T cell therapies, cancer vaccines, or checkpoint blockade inhibitors) by creating a therapeutic window for patients, thus stimulating a stronger overall immune response.Fig. 1Transforming tumor-associated macrophages into tumoricidal cells using mRNA nanoparticles. We developed an injectable nanocarrier delivering in vitro-transcribed mRNA encoding M1-polarizing transcription factors as a method to rationally reprogram tumor-associated macrophages (TAMs) for therapeutic purposes without causing systemic toxicity. Illustrated

Read the complete text